CRX.L Regulatory News (CRX)

31 Aug 2007 09:35

Cyprotex PLC31 August 2007 31 August 2007 Cyprotex PLC ("Cyprotex" or "the Company") Total Voting Rights and Share Capital Cyprotex PLC (AIM: CRX), the drug discovery technology and information companyis required to notify the market of the following: Cyprotex's issued share capital consists of 138,618,844 ordinary shares with anominal value of 0.1 pence each, with voting rights. Cyprotex does not hold anyordinary shares in Treasury. Therefore, the total number of voting rights in Cyprotex is 138,618,844. The above figure of 138,618,844 shares may be used by shareholders as thedenominator for the calculations by which they will determine if they arerequired to notify their interest in, or a change to their interest in, Cyprotexunder the Financial Service Authority's Disclosure and Transparency Rules. - Ends - For further information:Cyprotex PLCRobert Morrisson Atwater Tel: +44 (0) 1625 505100Chairman & Chief Executive OfficerRussell GibbsChief Financial Officeriir@cyprotex.com www.cyprotex.com This information is provided by RNS The company news service from the London Stock Exchange